Cargando…

Dynamics of HMBG1 (High Mobility Group Box 1) during radiochemotherapy correlate with outcome of HNSCC patients

PURPOSE: High Mobility Group Box 1 (HMGB1) protein has been described as a consensus marker for immunogenic cell death (ICD) in cancer. To personalize treatments, there is a need for biomarkers to adapt dose prescription, concomitant chemotherapy, and follow-up in radiation oncology. Thus, we invest...

Descripción completa

Detalles Bibliográficos
Autores principales:	Clasen, Kerstin, Welz, Stefan, Faltin, Heidrun, Zips, Daniel, Eckert, Franziska
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8789630/ https://www.ncbi.nlm.nih.gov/pubmed/34671818 http://dx.doi.org/10.1007/s00066-021-01860-8

Ejemplares similares

Plasma sICAM-1 Correlates with Tumor Volume Before Primary Radiochemotherapy of Head and Neck Squamous Cell Carcinoma Patients
por: Clasen, Kerstin, et al.
Publicado: (2022)

HMGB1 in depression: An overview of microglial HMBG1 in the pathogenesis of depression
por: Huang, Xiao, et al.
Publicado: (2023)

HMBG1 as a Driver of Inflammatory and Immune Processes in the Pathogenesis of Ocular Diseases
por: Liu, Yi, et al.
Publicado: (2018)

Resolution of atelectasis during radiochemotherapy of lung cancer with serious implications for further treatment. A case report
por: Braun, Lore Helene, et al.
Publicado: (2017)

Impact of MRI on target volume definition in head and neck cancer patients
por: Clasen, Kerstin, et al.
Publicado: (2023)

Effect of radiochemotherapy on T2* MRI in HNSCC and its relation to FMISO PET derived hypoxia and FDG PET
por: Wiedenmann, Nicole, et al.
Publicado: (2018)

SDF-1/CXCR4 expression in head and neck cancer and outcome after postoperative radiochemotherapy
por: De-Colle, Chiara, et al.
Publicado: (2017)

Correction to: Effect of radiochemotherapy on T2* MRI in HNSCC and its relation to FMISO PET derived hypoxia and FDG PET
por: Wiedenmann, Nicole, et al.
Publicado: (2018)

Independent validation of tumour volume, cancer stem cell markers and hypoxia-associated gene expressions for HNSCC after primary radiochemotherapy
por: Linge, Annett, et al.
Publicado: (2019)

High-mobility group box 1: role in ARDS
por: Ishizaka, A, et al.
Publicado: (2005)

High‐Mobility Group Box‐1 and Liver Disease
por: Gaskell, Harriet, et al.
Publicado: (2018)

High mobility group box 1 in diabetic nephropathy
por: Shi, Haitao, et al.
Publicado: (2017)

High Mobility Group Box 1 in Human Cancer
por: Rapoport, Bernardo L., et al.
Publicado: (2020)

Radiochemotherapy
Publicado: (1998)

High mobility group box 1: as a 'testament' mediator
por: Maruyama, I, et al.
Publicado: (2005)

The Role of High Mobility Group Box 1 in Innate Immunity
por: Lee, Shin-Ae, et al.
Publicado: (2014)

High Mobility Group Box Protein-1 in Wound Repair
por: Ranzato, Elia, et al.
Publicado: (2012)

High-Mobility Group Box 1 in Dry Eye Inflammation
por: Lema, Carolina, et al.
Publicado: (2018)

The Role of High Mobility Group Box 1 in Ischemic Stroke
por: Ye, Yingze, et al.
Publicado: (2019)

Role of High-Mobility Group Box-1 in Liver Pathogenesis
por: Khambu, Bilon, et al.
Publicado: (2019)

High Mobility Group Box 1 Protein in Cerebral Thromboemboli
por: Essig, Fabian, et al.
Publicado: (2021)

Urinary and serum levels of high mobility group box 1
por: Nakamura, Toshihiko, et al.
Publicado: (2023)

Sites of recurrent disease and prognostic factors in SCLC patients treated with radiochemotherapy
por: Bütof, Rebecca, et al.
Publicado: (2017)

Elevation of High-Mobility Group Protein Box-1 in Serum Correlates with Severity of Acute Intracerebral Hemorrhage
por: Zhou, Yu, et al.
Publicado: (2010)

The role of High Mobility Group Box 1 (HMGB1) in colorectal cancer
por: Süren, Dinç, et al.
Publicado: (2014)

Is serum high-mobility group box 1 (HMGB-1) level correlated with liver fibrosis in chronic hepatitis B?
por: Inkaya, Ahmet Cagkan, et al.
Publicado: (2017)

Mechanism and effectiveness of polymyxin B-immobilized fiber columns for removing mediators (HMBG-1, 2-arachidonoyl glycerol, anandamide, PAI-1, protein C and IL-6) in septic shock patients
por: Sakamoto, Y, et al.
Publicado: (2007)

Identification and Characterization of the Lamprey High-Mobility Group Box 1 Gene
por: Pang, Yue, et al.
Publicado: (2012)

Expression and Effects of High-Mobility Group Box 1 in Cervical Cancer
por: Pang, Xiaoao, et al.
Publicado: (2014)

High Mobility Group Box 1 Expression in Oral Inflammation and Regeneration
por: Yamashiro, Keisuke, et al.
Publicado: (2020)

High Mobility Group Box-1 and Blood–Brain Barrier Disruption
por: Nishibori, Masahiro, et al.
Publicado: (2020)

The Roles of High Mobility Group Box 1 in Cerebral Ischemic Injury
por: Gou, Xiaoyun, et al.
Publicado: (2020)

Role of Glycated High Mobility Group Box-1 in Gastric Cancer
por: Kishi, Shingo, et al.
Publicado: (2021)

Correlation between Serum Levels of High Mobility Group Box-1 Protein and Pancreatitis: A Meta-Analysis
por: Lin, Yan, et al.
Publicado: (2015)

Aberrant overexpression of transcription factor Forkhead box D1 predicts poor prognosis and promotes cancer progression in HNSCC
por: Li, Jin, et al.
Publicado: (2021)

Treatment outcome after radiochemotherapy in anal cancer patients staged with (18)F-FDG-PET-CT
por: Braun, L.H., et al.
Publicado: (2020)

High mobility group box 1 is a novel deacetylation target of Sirtuin1
por: Rabadi, May M., et al.
Publicado: (2014)

The role of high mobility group box 1 (HMGB1) in the pathogenesis of kidney diseases
por: Chen, Qingjie, et al.
Publicado: (2016)

Role of High Mobility Group Box 1 (HMGB1) in SCA17 Pathogenesis
por: Lee, Li-Ching, et al.
Publicado: (2014)

Developmental expression of high-mobility group box 1 (HMGB1) in the mouse cochlea
por: Liu, Wenjing, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_edd3r2264vvuc59or3g5r92ktn